Skip to main content
OpenTrials
Completed

NCT Number: NCT03871283

Anticoagulation and Antiplatelet Management During Perioperative Period

the investigators hypothesize that patients do not understand these therapies, and that they are poorly undertaken. In some cases, the anesthesiologist does not understand correctly the indication of the treatment due to lack of information and therefore does not know how to adapt it to the medical situation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anticoagulants and Bleeding Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

ERASME Hospital

Brussels, 1070, Belgium

About this study

the investigators hypothesize that patients do not understand these therapies, and that they are poorly undertaken. In some cases, the anesthesiologist does not understand correctly the indication of the treatment due to lack of information and therefore does not know how to adapt it to the medical situation.

the investigators want to investigate these transitions: how were they understood by patients, how were they performed, and how does this affect surgery, postoperative morbidity and mortality?

Anticoagulation for prevention of thromboembolic events will not be studied in this study.

The anesthesia team will not be particularly trained in anticoagulants and antiplatelets management to be close to actual care. In the Hospital the investigators have a guide written in 2013 in order to describe all the cases possible. The "control/ goal group" will be the patients who have undertaken strictly the protocol described for their cases in the guide.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 18 years old
  • Able to consent
  • Taking anticoagulants or antiplatelet drugs in the long term.

Exclusion criteria

  • Incapacitated adults
  • Minor patients

Treatment and study plan

Primary outcomes

  1. Ratio of well treated patient

    Time frame: 30 days

    Ratio of well treated patient

Secondary outcomes

  1. bleeding consequence (volume in mL)

    Time frame: 30 days

    bleeding consequence (volume in mL)

  2. Mortality Consequence

    Time frame: 30 Days

    percentage of death

  3. Blood Test Consequence

    Time frame: 30 Days

    deviation in percentage on INR

  4. Morbidity

    Time frame: 30 days

    percentage of rehospitalisation

Sponsors and collaborators

Lead sponsor

Erasme University Hospital

Other

Registry information

Official study title

Anticoagulation and Antiplatelet Management During Perioperative Period : a Daily Practice Cohort Prospective Study

Acronym: OMAHA

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 12, 2019
Registry last updated
Aug 12, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.